Clinical Research Center for Neurological Diseases of Guangxi Province, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
School of Pharmacy, Guilin Medical University, Guilin, 541001, China.
J Nanobiotechnology. 2020 Apr 19;18(1):61. doi: 10.1186/s12951-020-00616-3.
Primary intracerebral hemorrhage (ICH) is a leading cause of long-term disability and death worldwide. Drug delivery vehicles to treat ICH are less than satisfactory because of their short circulation lives, lack of specific targeting to the hemorrhagic site, and poor control of drug release. To exploit the fact that metal ions such as Fe are more abundant in peri-hematomal tissue than in healthy tissue because of red blood cell lysis, we developed a metal ion-responsive nanocarrier based on a phosphonated calix[4]arene derivative in order to deliver the neuroprotective agent dauricine (DRC) specifically to sites of primary and secondary brain injury. The potential of the dauricine-loaded nanocarriers for ICH therapy was systematically evaluated in vitro and in mouse models of autologous whole blood double infusion. The nanocarriers significantly reduced brain water content, restored blood-brain barrier integrity and attenuated neurological deficits by inhibiting the activation of glial cells, infiltration by neutrophils as well as production of pro-inflammatory factors (IL-1β, IL-6, TNF-α) and matrix-metalloprotease-9. These results suggest that our dauricine-loaded nanocarriers can improve neurological outcomes in an animal model of ICH by reducing inflammatory injury and inhibiting apoptosis and ferroptosis.
原发性脑出血 (ICH) 是全球导致长期残疾和死亡的主要原因。用于治疗 ICH 的药物输送载体由于其循环寿命短、缺乏对出血部位的特异性靶向以及药物释放控制不佳,效果并不理想。由于红细胞溶解,铁等金属离子在血肿周围组织中的含量比在健康组织中更为丰富,我们利用这一事实,开发了一种基于膦酸化杯[4]芳烃衍生物的金属离子响应性纳米载体,以便将神经保护剂蝙蝠葛碱 (DRC) 特异性递送至原发性和继发性脑损伤部位。我们系统地评估了载有 DRC 的纳米载体在体外和自体全血双输注小鼠模型中的 ICH 治疗潜力。纳米载体通过抑制神经胶质细胞的激活、中性粒细胞的浸润以及促炎因子 (IL-1β、IL-6、TNF-α) 和基质金属蛋白酶-9 的产生,显著降低了脑水含量,恢复了血脑屏障的完整性,并减轻了神经功能缺损。这些结果表明,我们载有 DRC 的纳米载体通过减少炎症损伤和抑制细胞凋亡和铁死亡,可以改善 ICH 动物模型的神经功能预后。